FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
EORTC-NCI-AACR International Conference
PUBLICATIONS
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients
AACR Special Conference: Metabolism and Cancer
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
